Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing in Patients With Minor Stroke or High Risk TIA (CYP2C19 and Stroke)
University of Alabama at Birmingham
200 participants
Apr 9, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.
Eligibility
Inclusion Criteria3
- Patients 18-89 years of age
- admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA
- eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well)
Exclusion Criteria5
- diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%)
- prescribed anticoagulation prior to stroke
- treated with intravenous thrombolysis
- treated with mechanical thrombectomy
- missing NIH Stroke Scale score
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
CYP2C19 is a gene that encodes an enzyme responsible for metabolizing several medications, including the antiplatelet drugs.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06943586